Orphan diseases and associated problems
نویسندگان
چکیده
Objective : to study the main aspects of assistance children with orphan diseases in Russian Federation. Materials and methods most relevant literature sources were studied that covered a concept various countries world Federation as well tactics regulation mechanisms for helping patients rare diseases. Results showed not all have legislative regulations patients. The United States Western Europe are advanced this regard. They clear criteria determining pathology number measures taken improve quality medical care These activities only aimed at improving health system but also encourage pharmaceutical companies develop produce medicines contribute research area. clinical cases article provide an idea diseases, complexity their diagnosis, severity course, drugs necessary help Conclusion been focus attention by national legislation past decades. Their extremely low prevalence human population creates difficulties timely provision qualified care, drug provision.
منابع مشابه
Rare diseases and orphan drugs.
According to the Regulation (EC) N. 141/2000 of the European Parliament and of the Council, rare diseases are life-threatening or chronically debilitating conditions, affecting no more than 5 in 10 000 persons in the European Community. It is estimated that between 6000 to 8000 distinct rare diseases affect up to 6% of the total EU population. Therefore, these conditions can be considered rare ...
متن کاملOrphan kidney diseases.
Rare kidney diseases are a unique subset of renal disorders that are often termed 'orphan' as a result of a multitude of reasons: the small number of patients with the consequent lack of well-defined natural history and course of many of these diseases, limited awareness among the medical community, and finally the significant cost of developing novel therapeutics which makes many of these dise...
متن کاملDrug repositioning for orphan diseases
The need and opportunity to discover therapeutics for rare or orphan diseases are enormous. Due to limited prevalence and/or commercial potential, of the approximately 6000 orphan diseases (defined by the FDA Orphan Drug Act as <200 000 US prevalence), only a small fraction (5%) is of interest to the biopharmaceutical industry. The fact that drug development is complicated, time-consuming and e...
متن کاملGlobal effort against rare and orphan diseases.
T he fifth International Congress on Rare Pulmonary Diseases and Orphan Drugs will take place in Milan, Italy, on February 8–9, 2013 (www.pulmonaryrarediseases. com). 10 yrs have passed since the first Congress was held. Since then, the Congress has taken place regularly every 2 yrs, with growing success and ever increasing numbers of participants and speakers from around the world. The Interna...
متن کامل[The pharmacist, rare diseases and orphan medicines].
Treatment of rare diseases is often complicated due to the difficulties posed by the research and development of medicines by the pharmacological industry. One of the greatest concerns of this group of patients, which is both scarce and diverse, is access to available medicines. The European Medicine Agency establishes the term orphan medicines and the incentives and bases for their commerciali...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: ??????????? ??????? ??? ??????
سال: 2021
ISSN: ['2618-7876', '2219-8075']
DOI: https://doi.org/10.21886/2219-8075-2021-12-2-28-35